Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study
Authors:
- Kai OzakiKOKai Ozaki
- Shingo HatakeyamaSHShingo Hatakeyama
- Shintaro NaritaSNShintaro Narita
- Kenichi HataKHKenichi Hata
- Takafumi YanagisawaTYTakafumi Yanagisawa
- Toshikazu TanakaTTToshikazu Tanaka
- Kyo TogashiKTKyo Togashi
- Tomoko HamayaTHTomoko Hamaya
- Teppei OkamotoTOTeppei Okamoto
- Hayato YamamotoHYHayato Yamamoto
- Takahiro YoneyamaTYTakahiro Yoneyama
- Yasuhiro HashimotoYHYasuhiro Hashimoto
- 15 December 2022
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (1) , 67-75
Abstract
Purpose We compared the real-world efficacy and medical costs for treatment with upfront docetaxel (DOC) and abiraterone acetate (ABI) up to progression-free survival 2 (PFS2) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Methods This multicenter retrospective study included 340 patients with mHSPC treated with either upfront DOC or upfront ABI between October 2015 and December 2021. We compared PFS2 and medical costs between the two treatment groups. PFS2 was defined as the time from first-line therapy to progression on second-line therapy. Medical costs were estimated using the National Health Insurance drug prices in 2022 in Japan. Results The upfront DOC and ABI groups included 107 and 233 patients, respectively. The incidence of metastatic castration-resistant PC progression was significantly higher in the upfront DOC group compared with the incidence in the upfront ABI group. However, no significant differences in PFS2 were observed between the two treatment groups. Monthly medical costs per patient were significantly higher in the upfront ABI group ($3453) compared with the costs in the upfront DOC group ($1239, P < 0.001). The cost differences were significantly influenced by differences in the length of androgen deprivation therapy monotherapy (DOC group, 13.4 months vs. ABI group, 0.0 months). Conclusions We observed a significant cost benefit in the upfront DOC group in Japanese real-world practice, while the PFS2 rates were similar between the groups. Upfront DOC was a more cost-effective option for men with mHSPC who were eligible for toxic chemotherapy.Keywords
Funding Information
- Japan Society for the Promotion of Science (19H05556, 20K09517)
This publication has 29 references indexed in Scilit:
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialJournal of Clinical Oncology, 2018
- Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolAnnals of Oncology, 2018
- Clinical and molecular features of treatment‐related neuroendocrine prostate cancerInternational Journal of Urology, 2018
- Current treatment strategies for advanced prostate cancerInternational Journal of Urology, 2017
- Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysisEuropean Journal of Cancer, 2017
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNew England Journal of Medicine, 2017
- Prostate cancer – major changes in the American Joint Committee on Cancer eighth edition cancer staging manualCA: A Cancer Journal for Clinicians, 2017
- Recent Trends in PSA Testing and Prostate Cancer IncidenceJAMA Oncology, 2016
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialThe Lancet, 2016
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008